Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Poitou Bernert, Christine (55908860000)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity
    (2021)
    De Groot, Cornelis Jan (56878477100)
    ;
    Poitou Bernert, Christine (55908860000)
    ;
    Coupaye, Muriel (24314690300)
    ;
    Clement, Karine (7005043037)
    ;
    Paschou, Stavroula A. (55632917800)
    ;
    Charmandari, Evangelia (7004635158)
    ;
    Kanaka-Gantenbein, Christina (55886598900)
    ;
    Wabitsch, Martin (7005831598)
    ;
    Buddingh, Emilie P. (6506603238)
    ;
    Nieuwenhuijsen, Barbara (57221731510)
    ;
    Marina, Ljiljana (36523361900)
    ;
    Johannsson, Gudmundur (56214660100)
    ;
    Van Den Akker, E.L.T. (7003723270)
    This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated. © 2021, The Author(s).
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity
    (2021)
    De Groot, Cornelis Jan (56878477100)
    ;
    Poitou Bernert, Christine (55908860000)
    ;
    Coupaye, Muriel (24314690300)
    ;
    Clement, Karine (7005043037)
    ;
    Paschou, Stavroula A. (55632917800)
    ;
    Charmandari, Evangelia (7004635158)
    ;
    Kanaka-Gantenbein, Christina (55886598900)
    ;
    Wabitsch, Martin (7005831598)
    ;
    Buddingh, Emilie P. (6506603238)
    ;
    Nieuwenhuijsen, Barbara (57221731510)
    ;
    Marina, Ljiljana (36523361900)
    ;
    Johannsson, Gudmundur (56214660100)
    ;
    Van Den Akker, E.L.T. (7003723270)
    This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated. © 2021, The Author(s).

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback